CTMX
CytomX Therapeutics Delivers Breakthroughs in Q4 2025 Results and Varseta Phase I Dose Expansion Data
CytomX Therapeutics has made significant strides in its Q4 2025 financial results and Varseta Phase I dose expansion data, marking a major milestone in the company's mission to revolutionize cancer treatment. The recent conference call highlighted the impressive progress made by the EpCAM-targeting Probody antibody-drug conjugate Varseta-M in